Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

Pfizer CEO Albert Bourla unpacks the impact of the nomination on 'The Claman Countdown.' ...

Though the big game has long been hallowed ground for some of the most entertaining and memorable commercials, they often don ...

Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of paying "kickbacks" ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Pfizer’s PFE 2024 revenue reached $63.6 billion, near the high end of its $61 billion-$64 billion guidance range. Management ...

Northfield Mount Hermon in Gill is where the late John Mitchell, once a Harwich resident, attended school from 1952-56. He ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health sector.

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to drive innovation in Pfizer’s drug discovery and development ...